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Abstract
Interleukin-11 (IL-11) is a pleiotropic cytokine that regulates the growth and development of
hematopoietic stem cells and decreases the proinflammatory mediators of cytokine and nitric oxide
production. In animal models of arthritis, treatment with recombinant human IL-11 (rhIL-11) reduces
both the level of synovitis and the histologic lesion scores in the joints.
The goal of this phase-I/II study in adults with rheumatoid arthritis (RA) was to evaluate the safety and
clinical activity of different doses and schedules of rhIL-11 in patients with active RA for whom
treatment with at least one disease-modifying antirheumatic drug had failed.
This was a multicenter, randomized, placebo-controlled trial that evaluated the safety and tolerability of
rhIL-11 in 91 patients with active RA. rhIL-11 was administered subcutaneously; patients were
randomized into one of five treatment groups (ratio of rhIL-11to placebo, 4:1). Patients were treated for
12 weeks with either 2.5 or 7.5 µg/kg of rhIL-11 or placebo twice per week or 5 or 15 µg/kg of rhIL-11
or placebo once per week. The status of each subject’s disease activity in accordance with the
American College of Rheumatology (ACR) criteria was assessed before, during, and after completion
of administration of the study drug.
Administration of rhIL-11 was well tolerated at all doses and schedules. The most frequent adverse
event was a reaction at the injection site. The data suggest a statistically significant reduction in the
number of tender joints (P < 0.008) at the 15 µg/kg once-weekly dose schedule but showed no overall
significant benefit at the ACR criterion of a 20% response.
The trial showed rhIL-11 to be safe and well tolerated at a variety of doses and schedules over a
12-week treatment period in patients with active RA. The only adverse event clearly associated with
rhIL-11 administration was reaction at the injection site.
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Introduction
Recombinant human interleukin-11 (rhIL-11) is a
pleiotropic cytokine that regulates the growth and devel-
opment of hematopoietic stem cells and decreases the
proinflammatory mediators of cytokine and nitric oxide pro-
duction [1]. Treatment with rhIL-11 decreases the produc-
tion of proinflammatory cytokines, including tumor
necrosis factor (TNF)-α and interleukin (IL)-1β, and inhibits
NF-κB binding activity [2,3,4]. In animal models both of
collagen-induced and adjuvant-induced arthritis, rhIL-11
reduced both the level of synovitis and the histologic
lesion score in the joints [5].
Rheumatoid arthritis (RA) is a chronic inflammatory
disease of unknown etiology. Its worldwide prevalence is
approximately 1% [6]. There appears to be no single ther-
apeutic regimen or combination of therapies that has con-
sistently been associated with sustained improvement (i.e.
remission) [7]. A number of disease-modifying drugs (e.g.
methotrexate) are available to treat RA but are limited by
significant toxicity requiring adjunct therapy, or are of vari-
able efficacy. There are currently a number of anticytokine
and other immune-modulating therapies in clinical trials
[8]. The proinflammatory cytokine TNF has been shown to
play a role in the pathogenesis of RA [9,10]. Etanercept
(sTNFR:Fc) and infliximab (chimeric anti-TNF monoclonal
antibody) have been shown to be efficacious in the treat-
ment of patients with RA for whom treatment with at least
one disease-modifying antirheumatic drug had previously
failed [11,12]; both of these biologicals have been
approved by regulatory agencies for the treatment of
patients with RA.
rhIL-11 has previously been assessed in a Phase-I/II,
masked, placebo-controlled trial in patients with active
Crohn’s disease. The data suggested clinical benefit as
assessed from the mean change from baseline in the
Crohn’s Disease Severity Index after 21 days at doses of
16 and 40 µg/kg per week (P < 0.05). The researchers
concluded that rhIL-11 was safe at the doses and sched-
ules used and had a therapeutic effect [13,14]. The find-
ings supported the initiation of a phase-I/II clinical trial in
patients with RA.
Materials and Methods
Patients
Men and women at least 18 years of age were eligible to
participate if they had met the American College of
Rheumatology (ACR) criteria for RA for at least one year
and were in functional Class I, II, or III [15]. All patients
had to have had at least one failed trial of a disease-
modifying antirheumatic drug (DMARD) and had to have
at least 10 painful and 10 swollen joints at entry. No
DMARD therapy was allowed within 4 weeks of random-
ization. Patients receiving nonsteroidal anti-inflammatory
drugs, corticosteroids (≤10 mg per day), or both were
allowed in the trial if they had been on stable doses for at
least four weeks before randomization. Required baseline
laboratory values included serum creatinine and blood
urea nitrogen ≤1.5 × the upper limit of normal and alanine
aminotranferase and aspartate aminotransferase ≤2.0 ×
the upper limit of normal. Exclusionary laboratory values
included a platelet count of > 500,000/mm3, hematocrit
< 30%, and a white-blood-cell count < 3000/mm3. Other
exclusionary criteria included use of intravenous or intra-
articular corticosteroids within four weeks of randomiza-
tion, any prior use of cyclosporine or cyclophosphamide,
use of any investigational agent within 30 days of random-
ization, severe extra-articular manifestations of RA, acute
infection requiring antibiotic therapy within two weeks of
randomization, other autoimmune disease (e.g. systemic
lupus erythematosus), or any other condition that the
investigator thought might have placed the patient at
undue risk if they had participated in the trial. Men and
women of childbearing potential were required to use
approved methods of birth control. Women had to have a
negative result on a test of serum beta human chorionic
gonadotropin at screening.
Medications including cyclosporine, cyclophosphamide,
and any DMARD were not allowed. The use of intravenous
or intra-articular corticosteroids was not permitted. The
following analgesics were permitted: acetaminophen,
acetaminophen with codeine, acetaminophen with oxy-
codone, and propoxyphene. Patients were instructed not
to take analgesics within 12 hours of their planned study
visit.
Study protocol
An Institutional Review Board approved the protocol at
each of the 12 participating centers. Patients gave prior
written, informed consent to any study-related procedures.
Within 14 days before randomization, patients had a com-
plete medical history taken and a complete physical exami-
nation. A standard hematology profile was prepared,
including white-blood-cell count with differential count,
and a serum-chemistry profile was prepared, consisting of
sodium, potassium, chloride, blood urea nitrogen,
creatinine, glucose, phosphorus, total bilirubin, alkaline
phosphatase, aspartate aminotransferase, alanine amino-
transferase, albumin, uric acid, total protein, C-reactive
protein (CRP), fibrinogen, and a microscopic urinalysis. An
additional serum specimen was taken on days 1, 28, 84,
and 112 to measure for the presence of IL-6. Screening
clinical assessments included vital signs, counts of tender
and swollen joints, the patient’s global assessment and
assessment of their pain, and a physician’s global assess-
ment using a 7-point Likert scale (0 = none, or good, to
7 = severe, or very bad). Rheumatoid factor was also mea-
sured. A serum pregnancy test was done in all female
patients of childbearing potential. Disease activity and clin-
ical laboratory values were assessed again on day 1, and
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then every 2 weeks for 12 weeks, and at 4 weeks post
dosing. Day-1 procedures were performed before the first
dose of study drug was administered.
Rheumatologists or trained study coordinators performed
clinical assessments. To minimize variability, the same
person assessed disease activity during the trial whenever
possible.
Patients could withdraw from the trial at any time for any of
the following reasons: at the patient’s request, if a serious
adverse event occurred, if a concomitant medication not
permitted by the protocol was required, or if a patient
became pregnant, did not comply with study-related pro-
cedures, or needed surgery.
Treatment
Twelve centers randomized patients, using a central ran-
domization to one of five treatment groups: placebo, 2.5 or
7.5 µg/kg of rhIL-11 twice per week, or 5.0 or 15 µg/kg of
rhIL-11 given subcutaneously once per week. The
maximum dose in any single injection was 1000 µg. The
study coordinator taught patients how to administer the
study drug subcutaneously themselves. Either rhIL-11 or a
placebo (saline) was supplied as 1 mg lyophilized powder
in a phosphate/glycine formulation and reconstituted with
1 ml water for injection.
Statistical analysis
The primary objective of this trial was to evaluate the
safety and tolerability of rhIL-11 given to patients with
active RA. The safety endpoints were the incidence and
severity of reported adverse events and abnormal labo-
ratory findings. Adverse events are reported without
regard to causality and are described for the study as a
whole and by treatment group. Descriptive statistics
summarizing the incidence and severity of adverse
events are presented.
The secondary objective of this trial was to evaluate and
characterize the clinical activity of rhIL-11. The endpoint
used to characterize clinical activity was the proportion of
patients whose disease improved according to the 20%
ACR criteria [16]. The overall proportion of patients whose
disease improved within each individual category of the
ACR criteria is also presented. Exploratory comparative
tests on differences in the proportions of improvement
between the rhIL-11-treated groups and the placebo
group were done, using a two-sided Fisher’s exact test.
Logistic regression was used to explore the effect of total
weekly dose, dosing schedule, treatment duration, and
outcome on clinical activity. Missing data were handled by
both the ad hoc last-observation-carried-forward method
and the worst-case-scenario method. In the last-observa-
tion-carried-forward approach, when an observation for a
12-week time point was lacking for a patient, the last avail-
able observed value was carried forward. In the worst-
case-scenario approach, dropouts were treated as fail-
ures. The sample size was based on an assumed 10%
placebo success rate. The sample size had a > 80%
power to detect a 0.51 difference from the placebo
success rate in at least one of the rhIL-11 treatment
groups at the α = 0.05 level of significance.
Results
Characteristics of patients
The pretherapy characteristics of the patients are sum-
marized in Table 1. Sixty-seven women and 24 men were
randomized to the study and 90 patients received at
least one dose of study drug. One patient was random-
ized but never received the study drug as they withdrew
consent prior to treatment. The mean age of all patients
was 51 years (range 21–83) and the mean time since
diagnosis was 12.6 years (range 1.2–40.3). No signifi-
cant differences between the pretherapy characteristics
of men and women were noted. The mean numbers of
tender and swollen joints in all patients at screening
were 27 and 20, respectively. Forty-nine of the 90
patients (54.4%) who were dosed completed 12 weeks
of dosing. The majority of patients (24 of 41 or 58.5%)
who discontinued early withdrew due to lack of clinical
effect. Eleven patients (12.2%) withdrew because of
adverse events. Of the remaining six patients, four with-
drew their consent, one was lost to follow-up, and one
received a prohibited medication. Patients who discon-
tinued from the trial were evenly distributed among all
the treatment groups.
Safety
rhIL-11 was well tolerated. No dose-limiting toxicities were
observed. In the 11 patients who withdrew because of an
adverse event, none of these events were considered to
be drug related. One patient died during the study, from
complications associated with a spontaneous pneumo-
thorax; this patient was in the placebo group. The only
adverse events clearly related to rhIL-11 were reactions at
the injection site, which were seen in 60.6% (43 of 71) of
patients who received rhIL-11 and none of the 19 placebo
recipients. The incidence of injection-site reactions was
not related to any dose or schedule. These reactions
(erythema or erythema with induration) were mild and
resolved within days after the study drug was discontin-
ued. There were no statistically significant differences in
the incidences of respiratory infections, non-respiratory
infections, or edema. A higher incidence of infection in the
rhIL-11 treated group (7.8%) than in the placebo group
(0%) was not statistically significant (P = 0.34). Clinical
trials with other agents that affect levels of circulating
TNF-α have also found more frequent, nonstatistical differ-
ences in the incidence of upper-respiratory infections [11].
Adverse events occurring in more than 5% of patients are
summarized in Table 2.
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No significant changes in hematology or chemistry para-
meters were noted during the study. There were no statis-
tically significant changes in fibrinogen levels or platelet
counts in rhIL-11 treated patients compared with placebo
during the study at all doses and schedules.
Disease activity
No clear therapeutic effect associated with the administra-
tion of rhIL-11 was observed. Figure 1 describes the data
using the 20% ACR criteria for response at the various
doses or schedules tested. The placebo response rate at
the 20% improvement criteria was unusually high (32%)
for a placebo-controlled trial. Several (6/19) patients in the
placebo group experienced a significant (> 50%) improve-
ment in their tender- and swollen-joint counts during the
study. These findings in the placebo group obscure any
comparative rhIL-11 benefit. Values for placebo-treated
patients regressed towards baseline during the follow-up
period in all analyses performed.
The group treated with rhIL-11 at 15 µg/kg once per week
produced a statistically significant improvement in tender-
joint counts (P = 0.007) at 12 weeks (Figure 1). The mean
percentage of improvement in the tender-joint count at this
dose and schedule was 31.8 (Figure 2). This trend was
consistent when an intent-to-treat (ITT) analysis was used
to evaluate changes from baseline in tender-joint count in
all rhIL-11 treated cohorts (P < 0.015). There is no obvious
reason why an improvement in tender-joint count were not
mirrored by changes in other clinical measurements.
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Table 1
Baseline demographics of patients enrolled in this clinical trial
Patients given various daily doses of rhIL-11
Characteristics Patients given placebo 2 × 2.5 µg/kg 1 × 5 µg/kg 2 × 7.5 µg/kg 1 × 15 µg/kg
Number of patients 19 19 17 16 20 
Age (years) 49.6 51.8 57.4 49.4 48.7 
Sex (%)
Male 32 16 18 44 25 
Female 68 84 82 56 75 
Race (%)
Black 5 11 0 13 5 
Asian 0 0 12 0 0 
Other 0 0 6 0 0 
Hispanic 11 11 6 13 10 
White 84 79 76 75 85 
Duration of disease (% of patients)
<2 years 0 5 6 13 15 
2–5 years 26 21 24 19 20 
>5 years 74 74 71 69 65 
Measures of arthritis activity
Swollen-joint counta 24 ± 11 20 ± 10 21 ± 10 17 ± 10 21 ± 10
Tender-joint counta 33 ± 13 29 ± 13 32 ± 16 26 ± 12 26 ± 13
Total counta 57 ± 18 49 ± 22 54 ± 24 43 ± 21 46 ± 22
Physician’s assessmentb 5.2 4.7 5.4 4.9 5.0 
Patient’s assessmentb 4.9 4.4 5.1 5.0 4.8 
Patient’s pain 4.6 4.1 5.4 5.3 4.8 
HAQc 1.4 1.3 1.5 1.4 1.4 
C-reactive protein 4.8 4.4 7.9 5.2 3.7 
aValues are means ± SD. b1 is best and 7 is worst. cHAQ = health assessment questionnaire; 0 is best and 3 is worst.
Comparative assessment (unadjusted for multiple compar-
isons) at the end-of-treatment time point revealed statisti-
cally significant correlations between serum levels of IL-6
and CRP to each of the six clinical outcomes (tender-joint
count, swollen-joint count, patient’s global assessment,
patient’s assessment of pain, physician’s global assess-
ment, score on health-assessment questionnaire). Correla-
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Table 2
Adverse events occurring in > 5% of all patients dosed with rhIL-11
Patients given various daily doses of rhIL-11
Patients given placebo 1 × 5 µg/kg 2 × 2.5 µg/kg 1 × 15 µg/kg 2 × 7.5 µg/kg All patients 
Adverse event (n = 19) (n = 17) (n = 19) (n = 19) (n = 16) (n = 90)
Reaction at injection site 0 11 (64.7) 13 (68.4) 11 (57.9) 8 (50.0) 43 (47.8)
Headache 5 (26.3) 1 (5.9) 5 (26.3) 5 (26.3) 1 (6.3) 17 (18.9)
Pharyngitis 1 (5.3) 2 (11.8) 3 (15.8) 3 (15.8) 6 (37.5) 15 (16.7)
Nausea 4 (21.1) 1 (5.9) 1 (5.3) 2 (10.5) 2 (12.5) 10 (11.1)
Asthenia 1 (5.3) 0 3 (15.8) 4 (21.1) 1 (6.3) 9 (10.0)
Rhinitis 1 (5.3) 3 (17.6) 3 (15.8) 1 (5.3) 1 (6.3) 9 (10.0)
Abdominal pain 2 (10.5) 3 (17.6) 2 (10.5) 0 1 (6.3) 8 (8.9)
Diarrhea 2 (10.5) 1 (5.9) 1 (5.3) 1 (5.3) 3 (18.8) 8 (8.9)
Pain 2 10.5) 4 (23.5) 1 (5.3) 0 1 (6.3) 8 (8.9)
Rash 2 (10.5) 1 (5.9) 0 5 (26.3) 0 8 (8.9)
Infection 0 1 (5.9) 1 (5.3) 4 (21.1) 1 (6.3) 7 (7.8)
Dizziness 1 (5.3) 2 (11.8) 0 1 (5.3) 2 (12.5) 6 (6.7)
Edema 1 (5.3) 4 (23.5) 1 (5.3) 0 0 6 (6.7)
Cough increased 0 2 (11.8) 1 (5.3) 1 (5.3) 1 (6.3) 5 (5.6)
Dyspepsia 1 (5.3) 0 2 (10.5) 0 2 (12.5) 5 (5.6)
Dyspnea 3 (15.8) 0 0 1 (5.3) 1 (6.3) 5 (5.6)
Flu syndrome 0 2 (11.8) 2 (10.5) 0 1 (6.3) 5 (5.6)
Values shown in parentheses are percentages.
Figure 1
Mean percentage of improvement in tender-joint counts (with last value
carried forward [LVCF]).
Figure 2
Proportion of patients with 20% improvement in ACR criteria (with last
value carried forward [LVCF]).
tion coefficients were moderate (r = 0.24 – 0.42) and all
corresponding, unadjusted, P-values were less than 0.03.
These were: tender-joint count versus IL-6 (P = 0.003);
swollen-joint count versus IL-6 (P = 0.026); tender-joint
count versus CRP (P = 0.001); swollen-joint count versus
CRP (P = 0.002). P-values of comparisons between the
other four clinical assessments and IL-6/CRP were
stronger, with all = 0.001.
Discussion
In this study, no therapeutic benefit of rhIL-11 (at the doses
and frequencies of administration studied) was found.
Some individual measurements of therapeutic effect
(tender-joint counts) and biologic activity (IL-6 levels) were
observed. rhIL-11 was well tolerated at all doses.
Except for the tender-joint count, none of the observed
disease activities was statistically different from placebo
according to the ACR criteria at the 20% improvement
level. The inability of rhIL-11 to bring about a statistically
significant improvement in the ACR 20% criteria may also
be the result of an inability of rhIL-11 to stimulate the syn-
thesis of acute-phase proteins, of the significant clinical
response of several placebo-treated patients, or of a lack
of adequate power of the study to show efficacy. Larger
clinical trails of rhIL-11 at higher or more frequent dosing
intervals and for a longer dosing period may provide more
definitive data on the safety and efficacy of rhIL-11 in the
treatment of patients with RA.
The mechanism of action of rhIL-11 in the treatment of
active RA most likely results from the ability of rhIL-11 to
reduce levels of TNF-α, IL-1β, and IL-12 p40. The anti-
inflammatory activity of rhIL-11 is mediated in part by
inhibition of NF-κB-dependent transcriptional activation
of proinflammatory cytokine genes. The ability of rhIL-11
to affect levels of IL-6 is also probably mediated through
this mechanism. An analysis of pharmacodynamic
markers in skin biopsies obtained from patients with
moderate psoriasis treated with rhIL-11 revealed lower
levels of INF-γ, TNF-α, and inducible nitric oxide than
before treatment.
Conclusion
These preliminary data suggest that rhIL-11 may be safely
administered to patients with active RA at a variety of
doses and schedules. No dose-limiting adverse event was
observed. The dose of 15 µg/kg of rhIL-11 once per week
suggested a minimal therapeutic effect, an improvement in
tender-joint counts. Further studies are warranted to find
out if higher or more frequent doses of rhIL-11 may be
safe and efficacious in treating RA.
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